GSK agreed to buy Nuvalent in a deal valued at $10.6 billion, adding a biotech firm that’s developing treatments for lung cancer as the British pharmaceutical company seeks to rebuild its oncology franchise. Sam Fazeli of Bloomberg Intelligence has more. (Source: Bloomberg)
GSK agreed to buy Nuvalent in a deal valued at $10.6 billion, adding a biotech firm that’s developing treatments for lung cancer as the British pharmaceutical company seeks to rebuild its oncology franchise. Sam Fazeli of Bloomberg Intelligence has more. (Source: Bloomberg)
<iframe src="https://statesidedaily.com/embed/cluster/702d5d9f4d605f127d8eb8fd04acfcf173c6c85c" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="GSK Agrees to Buy Nuvalent for $10.6 Billion"></iframe>
